NEW YORK (GenomeWeb News) – Qiagen this week announced a partnership and licensing options with Mayo Clinic. The deal covers the use of the IDH1 and IDH2 biomarkers for diagnosing cholangiocarcinoma and guiding treatment for the disease, a rare form of cancer that affects between 2,000 and 3,000 patients each year in the US. The partners will collaborate on developing new IDH1/2 products for cholangiocarcinoma. Financial terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genomic study of group B Streptococcus evolution, selection on the X chromosome in great apes, and more.

Changing the fat and fiber content of people's diets affects their gut microbiome, metabolome, and colon cancer risk, researchers say.

Broken links are found throughout academic publications, and some services are trying to combat such link decay.

Nick Stockton at Wired says that a pause in studying genome-editing tools should be used to find a path forward.